Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Breast cancer primary tumor ER expression pattern predicts its expression concordance in matched synchronous lymph node metastases

Authors: Juan Zhao, Chunxiu Hu, Cheng Wang, Wei Yu, Yinglu Guo, Minghan Shi, Yongjie Shui, Qichun Wei

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Estrogen receptor (ER) expression is important for treatment selection and prognostication of breast cancer patients. Although the metastases are the main targets of endocrine therapy, ER status is often based on the primary tumor. However, ER expression in breast cancer primary lesion may not match with its synchronous metastatic lesions in some cases. In this study, we analyzed ER expression concordance between breast cancer primary tumor and metastatic lesions.

Methods

Paraffin blocks of 100 primary breast invasive ductal carcinoma cases with axillary lymph node metastases were collected. Five tissue cores were punched out from individual primary breast cancer, and one tissue core from each lymph node metastases to assemble tissue microarrays for ER staining. Samples were then scored as 0, 1+, 2+, and 3+ according to the number and intensity of ER stained tumor cells.

Results

For cases with ER 3+ (strong expression) in all cores of primary lesions (n = 38), ER expression in metastatic lymph node was found in 94.7% of the patients. 91.0% of the metastatic lymph nodes were ER positive, and 84.3% of them to be 3+. Among the 46 cases of ER negative expression in all cores of primary lesions, 39 of them had all the metastatic nodes being ER negative, and ER negative nodes were seen in 95.7% of the metastases. As for 16 cases of ER inconsistent expression in primary lesions, 4 cases showed negative ER expression in all metastatic nodes, 2 cases displayed diffuse consistent ER 3+ expression, and 10 cases displayed variant ER expression.

Conclusions

The findings suggest that ER expression concordance between breast cancer primary lesion and its matched metastatic lesions could be estimated by primary tumor ER expression pattern.
Literature
3.
go back to reference Ataseven B, Gologan D, Gunesch A, et al. HER2/neu, topoisomerase 2a, estrogen and progesterone receptors: discordance between primary breast Cancer and metastatic axillary lymph node in expression and amplification characteristics. Breast Care (Basel). 2012;7(6):465–70. https://doi.org/10.1159/000345467.CrossRef Ataseven B, Gologan D, Gunesch A, et al. HER2/neu, topoisomerase 2a, estrogen and progesterone receptors: discordance between primary breast Cancer and metastatic axillary lymph node in expression and amplification characteristics. Breast Care (Basel). 2012;7(6):465–70. https://​doi.​org/​10.​1159/​000345467.CrossRef
6.
go back to reference Kuukasjärvi T, Karhu R, Tanner M, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997;57(8):1597–604.PubMed Kuukasjärvi T, Karhu R, Tanner M, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997;57(8):1597–604.PubMed
Metadata
Title
Breast cancer primary tumor ER expression pattern predicts its expression concordance in matched synchronous lymph node metastases
Authors
Juan Zhao
Chunxiu Hu
Cheng Wang
Wei Yu
Yinglu Guo
Minghan Shi
Yongjie Shui
Qichun Wei
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-5217-5

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine